Bone Indices in Thyroidectomized Patients on Long-Term Substitution Therapy with Levothyroxine Assessed by DXA and HR-pQCT

Table 2

Biochemical characteristics of included patients on long-term treatment with levothyroxine and matched controls. Median with interquartile (25%–75% percentiles) range.

	Reference range	Patients; ( = 49)	Controls; ( = 49)	value
Plasma
25-Hydroxyvitamin D (nmol/L)	50–160	75.9 (55.7–93.4)	65.9 (47.6–87.5)	0.07
PTH (pmol/L)	1.6–6.9	3.7 (3.0–4.8)	4.6 (3.5–5.1)	<0.05
TSH (10^3 IU/L)	0.30–4.50	2.32 (1.33–3.48)	2.00 (1.42–2.81)	0.24
T3 (nmol/L)	1.10–2.50	1.51 (1.34–1.69)	1.64 (1.47–1.86)	<0.01
T4 (nmol/L)	60–140	104 (94–120)	90 (78–100)	<0.001
T4-uptake (no unit)	0.80–1.30	1.05 (1.00–1.09)	1.04 (1.02–1.09)	0.93
T4/T3 ratio		70 (61–84)	53 (49–60)	<0.001
Calcium, total (mmol/L)	2.00–2.55	2.32 (2.27–2.37)	2.34 (2.28–2.40)	0.22
Calcium, ionized (mmol/L)	1.18–1.32	1.19 (1.17–1.22)	1.21 (1.18–1.23)	<0.05
Phosphate (mmol/L)	0.76–1.41	1.01 (0.91–1.12)	1.01 (0.86–1.14)	0.63
Magnesium (mmol/L)	0.70–1.10	0.86 (0.84–0.89)	0.84 (0.81–0.88)	<0.05
Albumin (g/L)	36–45	40 (38.5–42.0)	40 (38.0–41.5)	0.36
Creatinine (µmol/L)	45–90	68 (61–82)	67 (61–75)	0.38
eGFR (mL/min)	>60	82 (71–89)	83 (74–90)	0.28
Bone specific alkaline phosphatase (U/L)	12–50	23.2 (19.6–29.6)	23.6 (20.5–28.6)	0.90
PINP (µg/L)	20–93	43.1 (34.5–55.5)	49.4 (33.4–58.5)	0.65
Osteocalcin (µg/L)	10–55	21.8 (18.4–26.8)	22.7 (17.6–28.7)	0.76
CTX (µg/L)	0.03–0.84	0.39 (0.28–0.52)	0.37 (0.26–0.56)	0.87